Inactive Instrument

Analyst Reco. ISIS Pharmaceuticals, Inc. Nasdaq

Equities

US4643301090

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

Stifel Adjusts Ionis Pharmaceuticals Price Target to $53 From $50, Maintains Hold Rating	27/06	MT
ANALYST RECOMMENDATIONS : Home Depot, Apple, Micron Technology, Anglo American, United Utilities...	21/06
Ionis Pharmaceuticals Insider Sold Shares Worth $644,640, According to a Recent SEC Filing	21/06	MT
Bernstein Upgrades Ionis Pharmaceuticals to Market Perform From Underperform, Adjusts Price Target to $44 From $37	14/06	MT
ANALYST RECOMMENDATIONS : Adobe, Bank of America, Boeing, Nvidia, Wise...	14/06
Wells Fargo Adjusts Ionis Pharmaceuticals Price Target to $82 From $85, Maintains Overweight Rating	08/05	MT
Ionis Pharmaceuticals Insider Sold Shares Worth $256,277, According to a Recent SEC Filing	08/05	MT
Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform	10/04	MT
Oppenheimer Raises Ionis Pharmaceuticals' Price Target to $75 From $72, Maintains Outperform Rating	09/04	MT
Oppenheimer Adjusts Ionis Pharmaceuticals Price Target to $72 From $65, Maintains Outperform Rating	06/03	MT
Oppenheimer Adjusts Ionis Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating	26/02	MT
JPMorgan Chase Adjusts Price Target on Ionis Pharmaceuticals to $55 From $52, Maintains Neutral Rating	01/02	MT
RBC Lifts Price Target on Ionis Pharmaceuticals to $70 From $65, Says Survey Suggests Wainua Launch May Surprise to Upside; Outperform Kept	26/01	MT
Piper Sandler Adjusts Ionis Pharmaceuticals' Price Target to $62 From $60, Maintains Overweight Rating	19/01	MT
BofA Securities Upgrades Ionis Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $62 From $52	02/01	MT
Stifel Adjusts Price Target on Ionis Pharmaceuticals to $50 From $45, Maintains Hold Rating	18/12	MT
Goldman Sachs Raises Price Target on Ionis Pharmaceuticals to $28 From $25, Maintains Sell Rating	03/11	MT
Morgan Stanley Adjusts Price Target on Ionis Pharmaceuticals to $48 From $45, Maintains Equalweight Rating	03/11	MT
BofA Securities Upgrades Ionis Pharmaceuticals to Neutral From Underperform	23/23/23	MT
Raymond James Initiates Ionis Pharmaceuticals With Strong Buy Rating, Price Target is $63	29/23/29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. ISIS Pharmaceuticals, Inc. Nasdaq

Equities

US4643301090

Analyst Reco.

Filters